In murine model of melanoma, it has been demonstrated that VEGF-C was able to promote immune response via induction of CCL21 and tumor infiltration of naïve T cells before immunotherapy, indicating serum VEGF-C as a predictive biomarker for immunotherapy response [82]. The gene discussed is VEGFC; the disease is neoplasm.